1. Severe gastritis due to pembrolizumab treatment in a lung cancer patient
- Author
-
Noriko Hayama, Hiroaki Ihara, Yuichirou Honma, Yukinari Itoigawa, Kyoichi Kaira, and Mitsuhiro Fujii
- Subjects
Gastritis ,immune checkpoint inhibitors ,immune‐related adverse events ,inflammatory bowel disease ,pembrolizumab ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Immune checkpoint inhibitors (ICIs) are known to induce gastrointestinal adverse events. Colitis occurs most frequently, and gastritis is less common. A few case reports of gastritis induced by ICIs have indicated that colitis induced by cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) resembles inflammatory bowel disease (IBD) and that programmed death‐1/programmed death ligand‐1 (PD‐1/PD‐L1) inhibitor can also induce the same type of colitis. We herein encountered a case of gastritis arising after 25 cycles of pembrolizumab administration in which the pathological and endoscopic findings resembled those of IBD. ICIs may induce gastritis in a manner similar to the pathogenesis of IBD.
- Published
- 2020
- Full Text
- View/download PDF